You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

~ Buy the VELSIPITY (etrasimod arginine) Drug Profile, 2024 PDF Report in the Report Store ~

VELSIPITY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Velsipity patents expire, and when can generic versions of Velsipity launch?

Velsipity is a drug marketed by Pfizer and is included in one NDA. There are seven patents protecting this drug.

This drug has ninety-eight patent family members in twenty-seven countries.

The generic ingredient in VELSIPITY is etrasimod arginine. Two suppliers are listed for this compound. Additional details are available on the etrasimod arginine profile page.

DrugPatentWatch® Generic Entry Outlook for Velsipity

Velsipity will be eligible for patent challenges on October 12, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 12, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VELSIPITY?
  • What are the global sales for VELSIPITY?
  • What is Average Wholesale Price for VELSIPITY?
Summary for VELSIPITY
International Patents:98
US Patents:7
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Drug Prices: Drug price information for VELSIPITY
What excipients (inactive ingredients) are in VELSIPITY?VELSIPITY excipients list
DailyMed Link:VELSIPITY at DailyMed
Drug patent expirations by year for VELSIPITY
Drug Prices for VELSIPITY

See drug prices for VELSIPITY

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VELSIPITY
Generic Entry Date for VELSIPITY*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VELSIPITY

US Patents and Regulatory Information for VELSIPITY

VELSIPITY is protected by seven US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VELSIPITY is ⤷  Sign Up.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VELSIPITY

Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED

Methods of treating conditions related to the S1Preceptor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED

Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE

FDA Regulatory Exclusivity protecting VELSIPITY

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer VELSIPITY etrasimod arginine TABLET;ORAL 216956-001 Oct 12, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer VELSIPITY etrasimod arginine TABLET;ORAL 216956-001 Oct 12, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Pfizer VELSIPITY etrasimod arginine TABLET;ORAL 216956-001 Oct 12, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer VELSIPITY etrasimod arginine TABLET;ORAL 216956-001 Oct 12, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer VELSIPITY etrasimod arginine TABLET;ORAL 216956-001 Oct 12, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VELSIPITY

See the table below for patents covering VELSIPITY around the world.

Country Patent Number Title Estimated Expiration
China 108349891 ⤷  Sign Up
Japan 2018504398 S1P1受容体に関連する状態の処置方法 ⤷  Sign Up
Slovenia 2326621 ⤷  Sign Up
Japan 2021107425 自己免疫障害および炎症性障害の処置において有用な置換型1,2,3,4−テトラヒドロシクロペンタ[b]インドル−3−イル)酢酸誘導体 (SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVE USEFUL IN TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS) ⤷  Sign Up
Australia 2023200978 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.